CSCM Bone Health CPG -5-22 - 123

489. Oleson CV, Marino RJ, Formal CS, Modlesky CM, Leiby BE.
The effect of zoledronic acid on attenuation of bone loss
at the hip and knee following acute traumatic spinal cord
injury: a randomized-controlled study. Spinal Cord. 2020.
Aug;58(8):921-929
490. Shapiro J, Smith B, Beck T, et al. Treatment with zoledronic
acid ameliorates negative geometric changes in the proximal
femur following acute spinal cord injury. Calcif. Tissue Int.
2007;80(5):316-322.
491. Kajizono M, Sada H, Sugiura Y, et al. Incidence and
risk factors of osteonecrosis of the jaw in advanced
cancer patients after treatment with zoledronic acid or
denosumab: A retrospective cohort study. Biol. Pharm. Bull.
2015;38(12):1850-855.
492. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and
management of osteonecrosis of the jaw: A systematic
review and international consensus. J. Bone Miner. Res.
2015;30(1):3-23.
493. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated
osteonecrosis of the jaw: report of a task force of the
american society for bone and mineral research. J. Bone
Miner. Res. 2007;22(10):1479-1491.
494. Shane E, Burr D, Abrahamsen B, et al. Atypical
subtrochanteric and diaphyseal femoral fractures: Second
report of a task force of the American society for bone and
mineral research. J. Bone Miner. Res. 2014;29(1):1-23.
495. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical
nontraumatic diaphyseal fractures of the femur. J. Bone
Miner. Res. 2012;27(12):2544-2550.
496. Gilchrist NL, Frampton CM, Acland RH, et al. Alendronate
prevents bone loss in patients with acute spinal cord injury:
A randomized, double-blind, placebo-controlled study. J.
Clin. Endocrinol. Metab. URL http://jcem.endojournals.org/
cgi/reprint/92/4/1385. 2007;92(4):1385-1390.
497. Schnitzer TJ, Kim KH, Marks J, Yeasted R, Simonian N, Chen
D. Zoledronic Acid Treatment After Acute Spinal Cord Injury:
Results of a Randomized, Placebo-Controlled Pilot Trial. PM
R. 2016;8(9):833-843.
498. Morse LR. Osteoporosis prophylaxis in acute SCI. Spinal Cord
Ser Cases. 2019;5(1):27.
499. Watts NB, Roux C, Modlin JF, et al. Infections in
postmenopausal women with osteoporosis treated with
denosumab or placebo: coincidence or causal association?
Osteoporos Int. 2012;23(1):327-337.
500. Munier A, Gras V, Andrejak M, et al. Zoledronic acid and
renal toxicity: Data from French adverse effect reporting
database. Ann. Pharmacother. 2005;39(7-8):1194-1197.
501. Diel IJ, Weide R, Koppler H, et al. Risk of renal impairment
after treatment with ibandronate versus zoledronic acid:
a retrospective medical records review. Supportive Care in
Cancer. 2008;17:719-725.
502. Eser P, Frotzler A, Zehnder Y, et al. Relationship between the
duration of paralysis and bone structure: a pQCT study of
spinal cord injured individuals. Bone. 2004;34(5):869-880.
503. Coupaud S, McLean AN, Allan DB. Role of peripheral
quantitative computed tomography in identifying
disuse osteoporosis in paraplegia. Skeletal Radiol.
2009;38(10):989-995.
504. Coupaud S, McLean AN, Lloyd S, Allan DB. Predicting patientspecific
rates of bone loss at fracture-prone sites after spinal
cord injury. Disabil Rehabil. 2012;34(26):2242-2250.
505. Edwards WB, Schnitzer TJ, Troy KL. Bone mineral and
stiffness loss at the distal femur and proximal tibia in acute
spinal cord injury. Osteoporos Int. 2014;25(3):1005-1015.
506. Slade JM, Bickel CS, Modlesky CM, Majumdar S, Dudley GA.
Trabecular bone is more deteriorated in spinal cord injured
versus estrogen-free postmenopausal women. Osteoporos
Int. 2005;16(3):263-272.
507. Modlesky CM, Majumdar S, Narasimhan A, Dudley GA.
Trabecular bone microarchitecture is deteriorated in men
with spinal cord injury. J Bone Miner Res. 2004;19(1):48-55.
508. Eser P, Frotzler A, Zehnder Y, Denoth J. Fracture threshold
in the femur and tibia of people with spinal cord injury
as determined by peripheral quantitative computed
tomography. Arch Phys Med Rehabil. 2005;86(3):498-504.
509. Blight AR, Hseih J, Curt A, et al. The challenge of recruitment
for neurotherapeutic clinical trials in spinal cord injury. Spinal
Cord. 2019;57(5):348-359.
510. Product monograph pr forteo®. 2020; http://pi.lilly.com/ca/
forteo-ca-pm.pdf. Accessed June 14, 2021.
511. Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley
D, Andrews EB. Teriparatide did not increase adult
osteosarcoma incidence in a 15-year US postmarketing
surveillance study. J Bone Miner Res. 2021;36(2):244-251.
512. Haider IT, Simonian N, Saini AS, Leung FM, Edwards WB,
Schnitzer TJ. Open-label clinical trial of alendronate after
teriparatide therapy in people with spinal cord injury and
low bone mineral density. Spinal Cord. 2019;57(10):832-842.
513. Gifre L, Vidal J, Carrasco JL, et al. Denosumab increases
sublesional bone mass in osteoporotic individuals
with recent spinal cord injury. Osteoporosis Int.
2016;27(1):405-410.
514. Gordon KE, Wald MJ, Schnitzer TJ. Effect of parathyroid
hormone combined with gait training on bone density and
bone architecture in people with chronic spinal cord injury.
PM R. 2013;5(8):663-671.
515. Edwards WB, Simonian N, Haider IT, et al. Effects of
Teriparatide and Vibration on Bone Mass and Bone
Strength in People with Bone Loss and Spinal Cord
Injury: A Randomized, Controlled Trial. J Bone Miner Res.
2018;33(10):1729-1740.
109 | Clinical Practice Guidelines: Spinal Cord Medicine
http://pi.lilly.com/ca/ http://jcem.endojournals.org/
CSCM Bone Health CPG -5-22

Table of Contents for the Digital Edition of CSCM Bone Health CPG -5-22
